Intra-arterial chemotherapy and radiation therapy

Abstract

We discussed superselective intra-arterial cisplatin infusion with concomitant radiation therapy (RADPLAT) for patients with squamous cell carcinoma of the maxillary sinus (SCC-MS). Ninety-two patients with SCC-MS were treated by RADPLAT between 1999 and 2016 in Hokkaido University Hospital. The 5-year local control rate by RADPLAT and overall survival rate were 64.2% and 65.1%, respectively. We are currently undertaking a multi-institutional prospective trial of the superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy for patients with T4aN0M0 or T4bN0M0 locally advanced SCC-MS (JCOG 1212). The results of the dose-finding phase indicated that this therapy is safe and well-tolerated at 7 cycles of cisplatin 100mg/m², which was determined to be the recommended number of cycles for locally advanced SCC-MS. We consider SCC-MS as a suitable indication for RADPLAT. Therefore, we have to confirm the efficacy and safety of RADPLAT for SCC-MS. We expect that RADPLAT will be one of the treatments of choice for SCC-MS.